Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.
First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase 3 CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMate 459.
Methods
Archival or fresh tumor samples were collected before treatment and subjected to whole-exome sequencing, whole-transcriptome RNA sequencing, immunohistochemistry, and serological testing. Biomarkers were examined for association with clinical outcomes (ORR by blinded independent central review [BICR] per RECIST v1.1, progression-free survival [PFS] by BICR, and OS).
Results
The minimum follow-up was 33.6 months. In the nivolumab arm, 201, 230, 343, and ≥ 293 patients were evaluable by whole-exome sequencing, RNA sequencing, immunohistochemistry, and serology; 199, 239, 334, and ≥ 279 patients were evaluable in the sorafenib arm, respectively. Baseline tumor mutational burden was not predictive of survival with nivolumab. OS outcomes with sorafenib were improved in patients with mutated vs. wild-type Wnt/β-catenin pathway; consequently, OS was improved with nivolumab vs. sorafenib in patients with unaltered Wnt/β-catenin pathway (HR 0.66; 95% CI 0.47-0.91). High T-cell inflammation gene signature score and tumors with high programmed death ligand 1 levels (combined positive score ≥10) had improved OS with nivolumab vs. sorafenib (HR 0.68; 95% CI 0.47-0.98 and HR 0.55; 95% CI 0.33-0.93, respectively); PFS and ORR were also improved. Among circulating blood biomarkers, high interferon-γ, low pro-collagen 11, and low frequency of granulocytic myeloid-derived suppressor cells were associated with improved nivolumab efficacy vs. sorafenib.
Conclusions
These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death-1 inhibition.
IMPACT AND IMPLICATIONS
Nivolumab demonstrated a higher objective response rate and favorable safety profile as first-line treatment compared with sorafenib for patients with advanced HCC in the CheckMate 459 trial, yet did not show a significant improvement in overall survival. The exploratory analyses presented here have identified several candidate biomarkers that may be associated with efficacy of nivolumab in the first-line setting vs. sorafenib. These findings support additional studies to identify patients who may benefit from programmed death-1 inhibition treatment.
CLINICAL TRIAL NUMBER
NCT02576509.
These results show that pembrolizumab is a highly active agent in ccRCC and nccRCC and insights from the comprehensive analysis of RCC tumor molecular components and ctDNA may facilitate progress toward effective, biomarker-driven precision treatment in advanced RCC.
D. McDermott, S. Signoretti, J. Lee et al.· Annals of Oncology· 1 citation
In this two-center retrospective cohort, nivolumab was associated with longer PFS and OS than axitinib in the second-line treatment of mRCC, and these associations remained significant after adjustment for IMDC risk group and year of treatment initiation.
Irfan Bugday, İlknur Deliktaş Onur, M. Inanc et al.· Journal of Clinical Medicine· 0 citations
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...
É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al.· The Oncologist· 0 citations
Objective This study aimed to evaluate the efficacy and safety of sintilimab combined with anlotinib and chemoradiotherapy as first-line treatment for driver gene-negative oligometastatic non-small cell lung cancer (NSCLC). Methods This retrospective study included patients with driver gene-negative oligometastatic NSC...
INTRODUCTION
After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV.
METHODS
This retrospective, m...
Min-Ji Lee, Su-Bin Lim, J. Shim et al.· Hepatology International· 0 citations
Final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups.
T. Bauer, J. Martini, B. Besse et al.· Journal of Thoracic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.